In a recent trial, patients on Orforglipron 36 mg lost 19.7 lbs, a 73.6% greater relative weight loss than those on oral semaglutide 14 mg. However, 9-10% of Orforglipron patients stopped treatment due to adverse events, compared to 4-5% of oral semaglutide patients. Orforglipron offers significantly better weight loss and HbA1c reduction, but at the cost of substantially higher gastrointestinal side effects and treatment discontinuation. This presents a clear choice for patients and prescribers: maximum efficacy or better tolerability. A segmented market will likely emerge, with Orforglipron targeting those prioritizing aggressive results despite side effects.
Orforglipron
Best for: Patients seeking maximal weight loss and HbA1c reduction who can tolerate gastrointestinal side effects.
Orforglipron consistently outperformed oral semaglutide in weight loss and HbA1c reduction. Trials showed 74.7% of body weight reduction maintained, compared to 49.2% with placebo, according to Nature. This small-molecule pill works for up to two days and can be taken with or without food. Regulators in over 40 countries have received submissions, with potential U.S. action for obesity expected in Q2 2026.
Strengths: Superior weight loss and HbA1c reduction; Oral administration without fasted state requirement; Long duration of action (up to two days) | Limitations: Gastrointestinal events occurred in 44.1% to 70.4% of patients; 9-10% stopped due to adverse events | Price: Out-of-pocket cost $149 to $349
Oral Semaglutide
Best for: Patients prioritizing tolerability and convenience over maximal weight loss, particularly those with type 2 diabetes or cardiovascular disease risk.
Oral semaglutide demonstrated less weight loss and HbA1c reduction compared to orforglipron. Gastrointestinal side effects affected 37-45% of patients, with 4-5% stopping treatment due to adverse events. This peptide lasts a full week but requires a fasted state for administration. It is approved for type 2 diabetes and cardiovascular disease risk reduction.
